Home Endocrinology & Hormones Adrenergic Receptor inhibitor 3-Nitro-L-tyrosine

research use only

3-Nitro-L-tyrosine Adrenergic Receptor inhibitor

Cat.No.S6345

3-Nitro-L-tyrosine (3-NT, N-Tyr, MNT), synthesized from L-tyrosine by peroxynitrite, is a product of nitric oxide and superoxide. This compound inhibits the hemodynamic responses to angiotensin II, possibly through the inhibition of alpha 1-adrenoceptor-mediated events.
3-Nitro-L-tyrosine Adrenergic Receptor inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 226.19

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S634501 DMSO]2 mg/mL]false]Water]1 mg/mL]false]Ethanol]Insoluble]false Purity: 99.50%
99.50

Chemical Information, Storage & Stability

Molecular Weight 226.19 Formula

C9H10N2O5

 Storage (From the date of receipt) 3 years -20°C powder
CAS No. 621-44-3 -- Storage of Stock Solutions

Synonyms 3-NT, N-Tyr, MNT Smiles NC(CC1=CC(=C(O)C=C1)[N+]([O-])=O)C(O)=O

Solubility

In vitro
Batch:

DMSO : 2 mg/mL ( (8.84 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 1 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
alpha 1-adrenoceptor [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06126315 Not yet recruiting
Amyotrophic Lateral Sclerosis
Mario Negri Institute for Pharmacological Research|University of Sydney|FightMND
 June 2024 Phase 2|Phase 3
NCT05258669 Recruiting
COVID-19
Ocugen
 February 20 2022 Phase 2|Phase 3
NCT04259255 Active not recruiting
Amyotrophic Lateral Sclerosis|ALS
Mitsubishi Tanabe Pharma America Inc.|Massachusetts General Hospital
 October 21 2019 --
NCT03456882 Completed
Amyotrophic Lateral Sclerosis
Mario Negri Institute for Pharmacological Research|ALS Association|Get out ONLUS
 May 30 2017 Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map